

## References

S-32

1. Hackett G. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. *BJU International*. 2016;118:804-813.
2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, et al. Testosterone therapy in men with hypogonadism: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2018;103(5):1715-1744.
3. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency:AUA guideline. *J Urol*. 2018 Aug;200(2):423-432.
4. Donovitz G. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1million procedures. *Ther Adv Endocrinol Metab* 2021;12:1–11.
5. Rotker K, Alavian M, Nelson B, et al. Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia. *Asian J Androl*. 2018;10:4103.
6. Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Endocrinol Metab*. 2018;103(5):1745-1754.